Moderna, Inc. · MRNA · Next earnings

Moderna, Inc. reports Friday, Nov 6, 2026

MRNA reports before market open with consensus EPS at $-1.10 and revenue at $890.3M. Last quarter: Moderna: Q2 revenue beat, pipeline progress, trial risks remain

Reports Before market open1 day awayDate estimated Healthcare

What the street expects

Consensus for the coming report
Consensus EPS $-1.10 Calendar consensus
Consensus revenue $890.3M Calendar consensus
Report date Nov 6, 2026 Friday, date estimated
Session Before market open 1 day away

Where MRNA left off: FY2026 Q2

Full report

Moderna: Q2 revenue beat, pipeline progress, trial risks remain

EPS surprise +3.0% Reported $-1.97 vs $-2.03
Revenue surprise +40.9% Reported $145.0M vs $102.9M
Stock move -5.4% Event window
Subsequent drift +151.7% Up to 20 sessions

Management maintained its guidance stance, reaffirmed up to 10% 2026 revenue growth, and lowered cash-cost guidance.

What to watch on the call

Carried forward from the last transcript

Risks management flagged

  • The $950 million litigation settlement will affect cash flow.
  • Declining COVID vaccination rates could pressure revenue.
  • Regulatory approvals and pricing negotiations remain uncertain.
  • Timing and outcomes of Intismeran and norovirus readouts are unresolved.
  • Manufacturing capacity could constrain new launches if demand exceeds output.

Questions analysts left open

  • Timing and statistical powering of the Intismeran Phase III melanoma interim analysis.
  • Norovirus vaccine efficacy and interim study design.
  • Flu-vaccine strain selection for 2027 and pricing strategy.
  • Manufacturing scalability for new launches.
  • Effectiveness of the AI-driven neoantigen selection algorithm.

Ask FN2 about MRNA next report

Transcript, numbers and history already loaded
What should I watch for in MRNA's next earnings report?How did MRNA guide last quarter, and is consensus above or below that?Give me the bull and bear case going into MRNA earnings.

Free account. Your question opens in FN2 with this report's transcript and numbers attached.

Get the MRNA recap when the next report posts

One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.

Recent MRNA quarters

All MRNA earnings
-5.4%FY2026 Q2-1.2%FY2026 Q1+5.3%FY2025 Q4+3.3%FY2025 Q3

Sources

  1. FN2 corporate events calendar, resolved from the earnings calendar feed
  2. FN2 earnings calendar analyst consensus
  3. Earnings call transcript analysis, FY2026 Q2

Methodology

The report date comes from FN2's resolved corporate-events calendar and is marked estimated until the company confirms it. Consensus figures are the calendar's latest analyst estimates for the fiscal period and are not an FN2 forecast.

Risks and open questions are carried forward verbatim from FN2's structured analysis of the previous earnings call. Missing values stay missing and are never estimated.

By FN2 Research · Updated . For educational purposes only; not investment advice.